You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Headaches

Atogepant for treating migraine

  • Technology appraisal guidance
  • Reference number: TA1172
  • Published:  30 June 2026
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality impact assessment (guidance development) (PDF 131 KB)

    Published:
    30 June 2026

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 109 KB)

    Published:
    10 June 2026
  • Committee papers (PDF 3.09 MB)

    Published:
    10 June 2026
  • Equality impact assessment (downloadable version) (PDF 131 KB)

    Published:
    10 June 2026

Invitation to participate

  • Final scope (PDF 146 KB)

    Published:
    06 January 2026
  • Final stakeholder list (PDF 131 KB)

    Published:
    06 January 2026
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 192 KB)

    Published:
    06 January 2026
  • Equality impact assessment (scoping) (PDF 102 KB)

    Published:
    06 January 2026

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral (PDF 153 KB)

    Published:
    23 October 2025
  • Provisional stakeholder list post referral (PDF 143 KB)

    Published:
    23 October 2025
Back to top